Presented by NanoViricides: NNVC’s broad-spectrum antiviral NV-387 is now in Phase II for Ebola, and a separate Phase II program for Mpox is underway.
See what NNVC is building and the milestones ahead →
🔥 Good Morning from Top Tickers
🔥 This Cybersecurity Stock Just Jumped 7% Premarket
Raised outlooks are getting paid this morning. A cybersecurity name and a data management company are each up 7% after pairing a beat with a higher bar, and an upgrade has an energy stock close behind.
A highly anticipated AI IPO is doing its part too, lifting data storage names before the bell. The losers list is short: a retail giant is slipping despite a beat and a raise, and a video game publisher is giving back part of its pre-launch pop.
🤝 Sponsored By NanoViricides
NNVC: BUCKLE UP, BIOTECH TRADERS
Sponsored by Interactive Offers.
This has been disseminated on behalf of NanoViricides.
Could the Future of Antiviral Medicine Be Built Around One Broad-Spectrum Drug? NNVC is Taking Its NV-387 Candidate into the Fight Against Multiple Viral Threats!
NanoViricides (NYSE American: NNVC) is pursuing an ambitious idea: instead of chasing individual viruses as they mutate, develop an antiviral designed to interfere with a mechanism that multiple viruses may use to infect human cells.
Its investigational candidate, NV-387, is designed to mimic heparan sulfate proteoglycan (HSPG), a host-side feature involved in cell entry for certain viruses. The company believes this approach could make it harder for viruses to evade treatment through mutation, potentially giving the platform applications across multiple infectious diseases.
If successful, this host-targeting strategy could give NV-387 a potential advantage across multiple viral threats, making its clinical progress especially important to watch as researchers evaluate whether one treatment approach can address more than one dangerous infection!
NV-387 has moved into Phase II development for Ebola, while the company is also advancing a separate Phase II Mpox program. And there is another potential differentiator: an oral gummy formulation designed to dissolve in the mouth without water or conventional swallowing.
That could be especially relevant in outbreak settings where treatment logistics matter, although the formulation and the drug's clinical benefits still need to be established through testing.
With Ebola and Mpox programs underway, and additional viral applications under consideration, NNVC offers investors a developing clinical story with several potential milestones ahead.
🚀 Pre-Market Movers
The Biggest Gainers, Ranked
Palo Alto Networks (PANW): +7%
The cybersecurity player is surging after fiscal first-quarter results topped Wall Street’s expectations on both earnings and revenue. Management also guided the full fiscal year above what analysts were looking for. A beat paired with a higher bar is the combination the market pays for, and it is paying for it this morning.
Everpure (P): +7%
The data management company is climbing after raising its revenue outlook for the fiscal year ending January 2027. The new range sits above both its earlier call and what analysts were expecting, and third-quarter results beat on the top and bottom lines too. When a company lifts the bar and clears it in the same report, investors have little to argue with.
Bloom Energy (BE): +6%
BMO Capital Markets (BMO) upgraded the stock to Outperform after what its analysts described as positive meetings with management. The firm did trim its price target to $230 from $260, but that still implies about 35% upside from the last close. An upgrade that arrives with a lower target is an unusual pairing, and the market is siding with the upgrade.
Seagate Technology (STX): +5%
Data storage names are getting a lift as the Anthropic IPO, set for today, aims to breathe new life into the AI trade. Seagate supplies the mass storage infrastructure that AI models run on, and Western Digital (WDC) is up ~5% on the same read. Demand for storage was already strong, and a large chunk of it is expected to come from the AI lab going public.
“Running shos” shouldn’t return zero results. Gladly understands what your shoppers mean, typos and all, and finds the right products.
📉 Pre-Market Movers
The Biggest Losers, Ranked
Take-Two Interactive (TTWO): -3%
The video game publisher is giving back some of Wednesday’s gains, when the stock popped more than 6% ahead of the release of the much-anticipated “Grand Theft Auto VI.” After a run into the launch, a small pullback looks more like a breather than a verdict on the game.
Walmart (WMT): -2%
The retail giant beat third-quarter expectations and raised its full-year sales guidance, and the stock is slipping anyway. A beat and a raise that still gets sold is a reminder that clearing the bar is not always enough.
🤝 Sponsored By NanoViricides
NNVC IS THINKING WAY BIGGER
Sponsored by Interactive Offers.
This has been disseminated on behalf of NanoViricides.
One Antiviral Candidate Could Open the Door to a Much Bigger Opportunity! NNVC Is Advancing a Broad-Spectrum Approach Against Ebola, Mpox, and Other Dangerous Viruses
NanoViricides (NYSE American: NNVC) is advancing a potentially differentiated antiviral platform at a time when the need for new treatments remains urgent.
Its lead candidate, NV-387, has entered Phase II clinical development for Ebola in the Democratic Republic of the Congo, with a separate Phase II program targeting Mpox.
Unlike conventional approaches that focus primarily on viral proteins, NV-387 is designed to mimic a host-cell feature that certain viruses use to gain entry, potentially creating a broader strategy that could be less vulnerable to viral mutation.
The company is also exploring future applications against additional viral threats, including measles.
The opportunity extends beyond the science. NV-387 is being developed in an oral gummy formulation that dissolves in the mouth without requiring water or traditional swallowing, a delivery approach that could offer practical advantages in challenging treatment environments.
With clinical programs underway and multiple potential indications on the horizon, NNVC is building a story around one candidate with ambitions across several viral threats. A successful antiviral could potentially be relevant during future outbreaks, providing opportunities beyond the immediate clinical programs.
👀 What We’re Watching
Here’s One Ticker That’s Trending Today
UnitedHealth Group (UNH)
Retail traders are split on whether UnitedHealth’s selloff is an overreaction or a warning. Mentions on Reddit’s r/wallstreetbets jumped in the last 24 hours, and sentiment on StockTwits reads bullish, with dip buyers arguing that a proposed rule is not a final one while skeptics point to the political pressure building on big insurers.
The stock fell about 10% on Wednesday after regulators proposed expanding audits of Medicare Advantage plans, and shares are roughly flat in premarket trading. The rule is still only a proposal, so the next few sessions could show whether the dip buyers or the skeptics seem to have the better read.
✌️That’s it for today.
How are you feeling today?
17(b) Disclosure: This message is a paid advertisement for NanoViricides (NYSE: NNVC). The Street Sheet investor awareness services, including newsletters, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in The Street Sheet publications or presentations, including web content subject to change. The Street Sheet and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law Tag The Flag LLC dba The Street Sheet our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. Tag The Flag LLC dba The Street Sheet is not responsible for any gains or losses that result from the opinions expressed in newsletters, publications or presentations, including web content that it publishes electronically or in print. We strongly encourage all viewers to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca. NanoViricides (NYSE: NNVC) is a client of Interactive Offers who has contracted Tag The Flag LLC dba The Street Sheet. Through Interactive Offers, NanoViricides (NYSE: NNVC) agreed to pay Tag The Flag LLC dba The Street Sheet a one-time $3,000 fee in exchange for this advertisement, sent to its subscribers. Programs provided to subscribers and Companies by Tag The Flag LLC dba The Street Sheet are designed to help small-cap companies communicate their investment characteristics. Tag The Flag LLC dba The Street Sheet investor awareness services include newsletters, publications or presentations, including web content.


